A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Trial Profile

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms OPTIC
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 29 Nov 2016 According to an ARIAD Pharmaceuticals media release, data from this trial will be submitted to the American Society of Hematology (ASH) meeting in 2017.
    • 15 Sep 2016 According to an ARIAD Pharmaceuticals media release, data from the study will be presented at the European School of Haematology 18th Annual John Goldman Conference on Chronic Myeloid Leukemia 2016.
    • 09 May 2016 According to Incyte Corporation media release, company has agrred to fund a portion of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top